|
US7138486B2
(en)
|
1986-05-05 |
2006-11-21 |
The General Hospital Corporation |
Insulinotropic hormone derivatives and uses thereof
|
|
US6849708B1
(en)
|
1986-05-05 |
2005-02-01 |
The General Hospital Corporation |
Insulinotropic hormone and uses thereof
|
|
US5614492A
(en)
*
|
1986-05-05 |
1997-03-25 |
The General Hospital Corporation |
Insulinotropic hormone GLP-1 (7-36) and uses thereof
|
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
|
US6284727B1
(en)
|
1993-04-07 |
2001-09-04 |
Scios, Inc. |
Prolonged delivery of peptides
|
|
US5705483A
(en)
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
|
US20020006899A1
(en)
*
|
1998-10-06 |
2002-01-17 |
Pospisilik Andrew J. |
Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
|
|
ES2359031T3
(es)
*
|
1996-08-08 |
2011-05-17 |
Amylin Pharmaceuticals, Inc. |
Composición farmacéutica que comprende un péptido de exendina-4.
|
|
JP4798814B2
(ja)
*
|
1997-01-07 |
2011-10-19 |
アミリン・ファーマシューティカルズ，インコーポレイテッド |
食物摂取低減用のエキセンジンおよびそのアゴニストの使用
|
|
AU6586298A
(en)
*
|
1997-03-31 |
1998-10-22 |
Eli Lilly And Company |
Glucagon-like peptide-1 analogs
|
|
CA2283834A1
(en)
*
|
1997-03-31 |
1998-10-08 |
James Arthur Hoffmann |
Glucagon-like peptide-1 analogs
|
|
US7157555B1
(en)
*
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
|
WO1999025727A2
(en)
|
1997-11-14 |
1999-05-27 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
|
US7220721B1
(en)
*
|
1997-11-14 |
2007-05-22 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptides
|
|
AU1617399A
(en)
|
1997-12-05 |
1999-06-28 |
Eli Lilly And Company |
Glp-1 formulations
|
|
US6380357B2
(en)
|
1997-12-16 |
2002-04-30 |
Eli Lilly And Company |
Glucagon-like peptide-1 crystals
|
|
FR2777283B1
(fr)
*
|
1998-04-10 |
2000-11-24 |
Adir |
Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
DE19823831A1
(de)
*
|
1998-05-28 |
1999-12-02 |
Probiodrug Ges Fuer Arzneim |
Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
|
|
DE19828113A1
(de)
*
|
1998-06-24 |
2000-01-05 |
Probiodrug Ges Fuer Arzneim |
Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
|
|
EP1100530B1
(en)
*
|
1998-07-31 |
2003-10-08 |
Novo Nordisk A/S |
In-vitro stimulation of beta cell proliferation
|
|
US6720407B1
(en)
*
|
1998-08-28 |
2004-04-13 |
Eli Lilly And Company |
Method for administering insulinotropic peptides
|
|
EP1666054A1
(en)
|
1998-08-28 |
2006-06-07 |
Eli Lilly & Company |
Method for administering insulinotropic peptides
|
|
JP2002524514A
(ja)
|
1998-09-17 |
2002-08-06 |
イーライ・リリー・アンド・カンパニー |
タンパク質製剤
|
|
US20030176357A1
(en)
*
|
1998-10-06 |
2003-09-18 |
Pospisilik Andrew J. |
Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
|
|
US6284725B1
(en)
*
|
1998-10-08 |
2001-09-04 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
|
|
US7259136B2
(en)
*
|
1999-04-30 |
2007-08-21 |
Amylin Pharmaceuticals, Inc. |
Compositions and methods for treating peripheral vascular disease
|
|
CN1495198A
(zh)
*
|
1998-12-07 |
2004-05-12 |
�о���Ӧ�ÿ�ѧЭ��ɷ�����˾ |
胰高血糖素样肽-1的类似物
|
|
PL205713B1
(pl)
*
|
1998-12-07 |
2010-05-31 |
Sod Conseils Rech Applic |
Związki stanowiące analogi GLP-1, kompozycje farmaceutyczne zawierające takie związki oraz zastosowanie tych związków
|
|
SI1140148T1
(sl)
*
|
1998-12-22 |
2006-04-30 |
Lilly Co Eli |
Stabilna formulacija raztopine glukagonu podobnega peptida-1
|
|
CA2358107C
(en)
*
|
1998-12-22 |
2011-08-23 |
Eli Lilly And Company |
Shelf-stable formulation of glucagon-like peptide-1
|
|
US20050272652A1
(en)
|
1999-03-29 |
2005-12-08 |
Gault Victor A |
Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
|
|
US6605648B1
(en)
*
|
1999-04-06 |
2003-08-12 |
Phillips Plastics Corporation |
Sinterable structures and method
|
|
US6514500B1
(en)
*
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
|
US20090175821A1
(en)
*
|
1999-05-17 |
2009-07-09 |
Bridon Dominique P |
Modified therapeutic peptides with extended half-lives in vivo
|
|
EP1180121B9
(en)
|
1999-05-17 |
2004-09-08 |
Conjuchem, Inc. |
Long lasting insulinotropic peptides
|
|
ATE372782T1
(de)
|
1999-06-21 |
2007-09-15 |
Lilly Co Eli |
Synergitische verwendung von thiazolidinedionen und glucagon-ähnlichem peptid-1 und dessen agonisten für die behandlung von nicht-insulin- abhängigen diabetes
|
|
US6864234B1
(en)
|
1999-06-25 |
2005-03-08 |
Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. |
Somatostatin agonists
|
|
US9006175B2
(en)
*
|
1999-06-29 |
2015-04-14 |
Mannkind Corporation |
Potentiation of glucose elimination
|
|
ES2395096T3
(es)
|
1999-06-29 |
2013-02-08 |
Mannkind Corporation |
Purificación y estabilización de agentes farmacéuticos a base de péptidos y proteínas
|
|
DE19940130A1
(de)
*
|
1999-08-24 |
2001-03-01 |
Probiodrug Ges Fuer Arzneim |
Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
|
|
EP1741445B1
(en)
|
2000-01-21 |
2013-08-14 |
Novartis AG |
Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
|
|
US6448045B1
(en)
*
|
2000-03-10 |
2002-09-10 |
The Regents Of The University Of California |
Inducing insulin gene expression in pancreas cells expressing recombinant PDX-1
|
|
WO2001072290A2
(en)
*
|
2000-03-31 |
2001-10-04 |
Probiodrug Ag |
Method for the improvement of islet signaling in diabetes mellitus and for its prevention
|
|
JP2003530838A
(ja)
|
2000-04-12 |
2003-10-21 |
ヒューマン ゲノム サイエンシズ インコーポレイテッド |
アルブミン融合タンパク質
|
|
AU6479101A
(en)
*
|
2000-06-16 |
2002-01-02 |
Lilly Co Eli |
Glucagon-like peptide-1 analogs
|
|
KR100407792B1
(ko)
*
|
2000-08-02 |
2003-12-01 |
한국생명공학연구원 |
인간 글루카곤 유사펩타이드를 융합파트너로 이용한재조합 단백질의 제조방법
|
|
AR033390A1
(es)
|
2000-08-22 |
2003-12-17 |
Novartis Ag |
Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
|
|
KR100713234B1
(ko)
*
|
2000-10-02 |
2007-05-02 |
유에스브이 리미티드 |
메트포민을 함유하는 지속방출형 약학 조성물 및 이의제조방법
|
|
EP1328270A2
(en)
*
|
2000-10-27 |
2003-07-23 |
Probiodrug AG |
Method for the treatment of neurological and neuropsychological disorders
|
|
ATE416784T1
(de)
|
2000-12-01 |
2008-12-15 |
Takeda Pharmaceutical |
Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
|
|
AU2002228608A1
(en)
*
|
2000-12-13 |
2002-06-24 |
Eli Lilly And Company |
Amidated glucagon-like peptide-1
|
|
EP1390061A2
(en)
*
|
2000-12-13 |
2004-02-25 |
Eli Lilly And Company |
Chronic treatment regimen using glucagon-like insulinotropic peptides
|
|
EP1385549A2
(en)
*
|
2001-03-12 |
2004-02-04 |
Novartis AG |
Combination of nateglinide or repaglinide with at least one further antidiabetic compound
|
|
US6573237B2
(en)
|
2001-03-16 |
2003-06-03 |
Eli Lilly And Company |
Protein formulations
|
|
US20030130199A1
(en)
*
|
2001-06-27 |
2003-07-10 |
Von Hoersten Stephan |
Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
|
|
US7368421B2
(en)
*
|
2001-06-27 |
2008-05-06 |
Probiodrug Ag |
Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
|
|
EP1412384B1
(en)
*
|
2001-06-28 |
2007-12-26 |
Novo Nordisk A/S |
Stable formulation of modified glp-1
|
|
UA74912C2
(en)
*
|
2001-07-06 |
2006-02-15 |
Merck & Co Inc |
Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
|
|
US6642003B2
(en)
|
2001-08-02 |
2003-11-04 |
Cedars-Sinai Medical Center |
Human glucose-dependent insulin-secreting cell line
|
|
US20040214762A1
(en)
*
|
2001-08-16 |
2004-10-28 |
Hans-Ulrich Demuth |
Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphosphate concentration dependent on intracellular signal cascades
|
|
WO2003020201A2
(en)
*
|
2001-08-28 |
2003-03-13 |
Eli Lilly And Company |
Pre-mixes of glp-1 and basal insulin
|
|
US6844316B2
(en)
*
|
2001-09-06 |
2005-01-18 |
Probiodrug Ag |
Inhibitors of dipeptidyl peptidase I
|
|
US6911324B2
(en)
|
2001-10-18 |
2005-06-28 |
The Regents Of The University Of California |
Induction of beta cell differentiation in human cells
|
|
JP2005508360A
(ja)
*
|
2001-10-19 |
2005-03-31 |
イーライ・リリー・アンド・カンパニー |
Ｇｌｐ−１およびインスリンの二相混合物
|
|
US7332819B2
(en)
*
|
2002-01-09 |
2008-02-19 |
Micron Technology, Inc. |
Stacked die in die BGA package
|
|
ES2425738T3
(es)
|
2001-12-21 |
2013-10-17 |
Human Genome Sciences, Inc. |
Proteínas de fusión de la albúmina
|
|
AU2002364587A1
(en)
*
|
2001-12-21 |
2003-07-30 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US7105489B2
(en)
*
|
2002-01-22 |
2006-09-12 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for treating polycystic ovary syndrome
|
|
CN1332711C
(zh)
*
|
2002-02-20 |
2007-08-22 |
埃米球科技有限公司 |
施用glp－1分子的方法
|
|
US7141240B2
(en)
*
|
2002-03-12 |
2006-11-28 |
Cedars-Sinai Medical Center |
Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
|
|
WO2003080149A2
(en)
|
2002-03-20 |
2003-10-02 |
Mannkind Corporation |
Inhalation apparatus
|
|
US20030232761A1
(en)
*
|
2002-03-28 |
2003-12-18 |
Hinke Simon A. |
Novel analogues of glucose-dependent insulinotropic polypeptide
|
|
US20030191056A1
(en)
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
|
MXPA04012497A
(es)
|
2002-07-04 |
2005-07-14 |
Zealand Pharma As |
Glp-1 y metodos para tratar la diabetes.
|
|
US20080260838A1
(en)
*
|
2003-08-01 |
2008-10-23 |
Mannkind Corporation |
Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
|
|
US20040058876A1
(en)
*
|
2002-09-18 |
2004-03-25 |
Torsten Hoffmann |
Secondary binding site of dipeptidyl peptidase IV (DP IV)
|
|
ATE461212T1
(de)
*
|
2002-09-18 |
2010-04-15 |
Prosidion Ltd |
Sekundäre bindungsstelle von dipeptidylpeptidase iv (dp iv)
|
|
EP1543030A2
(en)
|
2002-09-25 |
2005-06-22 |
Theratechnologies Inc. |
Modified glp-1 peptides with increased biological potency
|
|
PL377591A1
(pl)
*
|
2002-10-02 |
2006-02-06 |
Zealand Pharma A/S |
Stabilizowane związki eksendyny-4
|
|
JP2006506386A
(ja)
*
|
2002-10-22 |
2006-02-23 |
ワラタ ファーマシューティカルズ， インコーポレイテッド |
糖尿病の処置
|
|
US7790681B2
(en)
*
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
|
US20040209803A1
(en)
*
|
2002-12-19 |
2004-10-21 |
Alain Baron |
Compositions for the treatment and prevention of nephropathy
|
|
RU2234703C1
(ru)
*
|
2002-12-18 |
2004-08-20 |
Мищенко Борис Петрович |
Способ количественного определения гликогемоглобина
|
|
WO2004060387A1
(en)
*
|
2002-12-27 |
2004-07-22 |
Diobex, Inc. |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
|
US7655618B2
(en)
*
|
2002-12-27 |
2010-02-02 |
Diobex, Inc. |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
|
EP1594530A4
(en)
|
2003-01-22 |
2006-10-11 |
Human Genome Sciences Inc |
HYBRID PROTEINS OF ALBUMIN
|
|
CN1750842A
(zh)
*
|
2003-02-19 |
2006-03-22 |
研究及应用科学协会股份有限公司 |
Glp－1的类似物
|
|
EA009366B1
(ru)
*
|
2003-03-19 |
2007-12-28 |
Эли Лилли Энд Компани |
Связанные с полиэтиленгликолем соединения гпп-1
|
|
JP2006523683A
(ja)
*
|
2003-04-15 |
2006-10-19 |
オッパーバス・ホールディング・ビー・ブイ |
タンパク質及び／またはポリペプチド及びコロイド粒子を含む医薬組成物
|
|
EP1961416B1
(en)
*
|
2003-05-05 |
2013-01-23 |
Probiodrug AG |
Use of inhibitors of glutaminyl cyclase for treating psoriasis, rheumatoid arthritis or atherosclerosis.
|
|
ATE462432T1
(de)
*
|
2003-05-05 |
2010-04-15 |
Probiodrug Ag |
Glutaminylcyclase-hemmer
|
|
ES2425221T3
(es)
*
|
2003-05-30 |
2013-10-14 |
Amylin Pharmaceuticals, Llc |
Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas
|
|
EP1633391B1
(en)
*
|
2003-06-03 |
2011-10-19 |
Novo Nordisk A/S |
Stabilized pharmaceutical peptide compositions
|
|
CN1812808B
(zh)
*
|
2003-06-03 |
2012-07-04 |
诺沃挪第克公司 |
稳定化的药物肽组合物
|
|
BRPI0410972C1
(pt)
*
|
2003-06-03 |
2021-05-25 |
Novo Nordisk As |
método para aumentar a vida de armazenagem de uma composição farmacêutica, composição farmacêutica, e, método para tratamento de hiperglicemia
|
|
KR20120007079A
(ko)
*
|
2003-10-15 |
2012-01-19 |
프로비오드룩 아게 |
글루타미닐 및 글루타메이트 사이클라제 이펙터의 용도
|
|
DK3300721T4
(da)
*
|
2003-11-20 |
2025-03-03 |
Novo Nordisk As |
Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
|
|
WO2005058252A2
(en)
*
|
2003-12-16 |
2005-06-30 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. |
Glp-1 pharmaceutical compositions
|
|
CA2551039C
(en)
|
2003-12-16 |
2013-01-29 |
Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R |
Analogues of glp-1
|
|
US20060286129A1
(en)
*
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
|
BRPI0507189A
(pt)
*
|
2004-01-30 |
2007-06-26 |
Waratah Pharmaceuticals Inc |
uso combinado de um agonista de glp-1 e compostos de gastrina
|
|
KR101099206B1
(ko)
|
2004-02-05 |
2011-12-27 |
프로비오드룩 아게 |
신규한 글루타미닐 시클라제 저해제
|
|
EP1729795B1
(en)
*
|
2004-02-09 |
2016-02-03 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
ES2328591T3
(es)
|
2004-04-23 |
2009-11-16 |
Conjuchem Biotechnologies Inc. |
Procedimiento para la purificacion de conjugados de albumina.
|
|
US20090069226A1
(en)
*
|
2004-05-28 |
2009-03-12 |
Amylin Pharmaceuticals, Inc. |
Transmucosal delivery of peptides and proteins
|
|
ATE486064T1
(de)
|
2004-08-20 |
2010-11-15 |
Mannkind Corp |
Katalyse der diketopiperazinsynthese
|
|
HUE025151T2
(en)
|
2004-08-23 |
2016-01-28 |
Mannkind Corp |
Diceto-piperazine salts for drug delivery
|
|
PL1789434T3
(pl)
*
|
2004-08-31 |
2014-07-31 |
Novo Nordisk As |
Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
|
|
DE102004043153B4
(de)
*
|
2004-09-03 |
2013-11-21 |
Philipps-Universität Marburg |
Erfindung betreffend GLP-1 und Exendin
|
|
CN106137952B
(zh)
*
|
2004-11-12 |
2020-11-17 |
诺和诺德公司 |
促胰岛素肽的稳定制剂
|
|
WO2006069779A1
(en)
*
|
2004-12-30 |
2006-07-06 |
F. Hoffmann-La Roche Ag |
Preparing of peptides with excellent solubility
|
|
WO2006069697A1
(en)
*
|
2004-12-30 |
2006-07-06 |
F. Hoffmann-La Roche Ag |
Colorimetrically assessing peptide characteristics
|
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
|
EP1853627A2
(en)
|
2005-02-11 |
2007-11-14 |
Amylin Pharmaceuticals, Inc. |
Gip analog and hybrid polypeptides with selectable properties
|
|
WO2006097535A2
(en)
*
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Peptide agonists of the glucagon family with secretin like activity
|
|
EP1896605A4
(en)
|
2005-06-07 |
2010-09-01 |
Univ Rockefeller |
Stimulation of proliferation of pancreatic B cells
|
|
NZ565535A
(en)
*
|
2005-06-30 |
2011-03-31 |
Ipsen Pharma Sas |
GLP-1 pharmaceutical compositions
|
|
US20070004616A1
(en)
*
|
2005-06-30 |
2007-01-04 |
Roland Cherif-Cheikh |
GLP-1 pharmaceutical compositions
|
|
GT200600381A
(es)
|
2005-08-25 |
2007-03-28 |
|
Compuestos organicos
|
|
KR101486397B1
(ko)
|
2005-09-14 |
2015-01-28 |
맨카인드 코포레이션 |
활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
|
|
PT1767545E
(pt)
|
2005-09-22 |
2010-02-05 |
Biocompatibles Uk Ltd |
Polipéptidos de fusão glp-1 (péptido 1 do tipo glucagom) com resistência aumentada à peptidase
|
|
GB0522295D0
(en)
*
|
2005-11-01 |
2005-12-07 |
Activotec Spp Ltd |
Peptides and uses thereof
|
|
WO2007051987A1
(en)
*
|
2005-11-01 |
2007-05-10 |
Activotec Spp Limited |
Insulinotropic compounds and uses thereof
|
|
WO2007053946A1
(en)
*
|
2005-11-09 |
2007-05-18 |
Conjuchem Biotechnologies Inc. |
Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
|
|
CN100374462C
(zh)
*
|
2005-11-21 |
2008-03-12 |
大连帝恩生物工程有限公司 |
截短胰高血糖素样肽1(sGLP-1)、制法及其应用
|
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
|
US8334257B2
(en)
|
2005-12-20 |
2012-12-18 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
|
CA2634495A1
(en)
*
|
2005-12-22 |
2007-06-28 |
Conjuchem Biotechnologies Inc. |
Process for the production of preformed conjugates of albumin and a therapeutic agent
|
|
KR20080096809A
(ko)
|
2006-02-22 |
2008-11-03 |
맨카인드 코포레이션 |
디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법
|
|
MX2008013304A
(es)
*
|
2006-04-20 |
2008-10-27 |
Amgen Inc |
Compuestos de peptido 1 tipo glucagon.
|
|
NZ573093A
(en)
*
|
2006-06-23 |
2012-01-12 |
Hoffmann La Roche |
Insulinotropic peptide synthesis
|
|
BRPI0714334A2
(pt)
*
|
2006-07-18 |
2013-05-14 |
Centocor Inc |
mimeticorpos de glp-1 humano aperfeiÇoados, composiÇÕes, mÉtodos e usos
|
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
|
TW200843794A
(en)
*
|
2006-12-21 |
2008-11-16 |
Centocor Inc |
Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles
|
|
JP2008169195A
(ja)
|
2007-01-05 |
2008-07-24 |
Hanmi Pharmaceutical Co Ltd |
キャリア物質を用いたインスリン分泌ペプチド薬物結合体
|
|
GB2448895A
(en)
*
|
2007-05-01 |
2008-11-05 |
Activotec Spp Ltd |
GLP-1 like compounds and uses thereof
|
|
US20100292133A1
(en)
|
2007-09-05 |
2010-11-18 |
Novo Nordisk A/S |
Truncated glp-1 derivaties and their therapeutical use
|
|
ES2672770T3
(es)
*
|
2007-09-05 |
2018-06-18 |
Novo Nordisk A/S |
Derivados del péptido-1 similar al glucagón y su uso farmacéutico
|
|
RU2467741C2
(ru)
|
2007-10-24 |
2012-11-27 |
Маннкайнд Корпорейшн |
Доставка активных веществ
|
|
US8785396B2
(en)
|
2007-10-24 |
2014-07-22 |
Mannkind Corporation |
Method and composition for treating migraines
|
|
CN101969927A
(zh)
*
|
2007-10-24 |
2011-02-09 |
曼金德公司 |
预防glp-1不良影响的方法
|
|
EP2205624B1
(en)
*
|
2007-10-27 |
2016-09-07 |
Corden Pharma Colorado, Inc. |
Insulinotropic peptide synthesis using solid and solution phase combination techniques
|
|
CN101918027A
(zh)
*
|
2007-11-02 |
2010-12-15 |
森托科尔奥索生物科技公司 |
半合成GLP-1肽-Fc融合构造、方法及其用途
|
|
JP2011506442A
(ja)
*
|
2007-12-11 |
2011-03-03 |
コンジュケム バイオテクノロジーズ インコーポレイテッド |
インスリン分泌性ペプチド結合体の製剤
|
|
US20100317057A1
(en)
|
2007-12-28 |
2010-12-16 |
Novo Nordisk A/S |
Semi-recombinant preparation of glp-1 analogues
|
|
US8485180B2
(en)
|
2008-06-13 |
2013-07-16 |
Mannkind Corporation |
Dry powder drug delivery system
|
|
ES2929343T3
(es)
|
2008-06-13 |
2022-11-28 |
Mannkind Corp |
Inhalador de polvo seco accionado por aspiración para la administración de fármacos
|
|
MX2010014240A
(es)
|
2008-06-20 |
2011-03-25 |
Mankind Corp |
Un metodo y aparato interactivo para perfilar en tiempo real esfuerzos de inhalacion.
|
|
EP3412300A1
(en)
*
|
2008-06-27 |
2018-12-12 |
Duke University |
Therapeutic agents comprising elastin-like peptides
|
|
TWI494123B
(zh)
|
2008-08-11 |
2015-08-01 |
Mannkind Corp |
超快起作用胰島素之用途
|
|
EP3228320B1
(de)
|
2008-10-17 |
2019-12-18 |
Sanofi-Aventis Deutschland GmbH |
Kombination von einem insulin und einem glp-1-agonisten
|
|
EP2358200A4
(en)
*
|
2008-11-17 |
2012-05-16 |
Merck Sharp & Dohme |
SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES
|
|
US8314106B2
(en)
|
2008-12-29 |
2012-11-20 |
Mannkind Corporation |
Substituted diketopiperazine analogs for use as drug delivery agents
|
|
WO2010105094A1
(en)
|
2009-03-11 |
2010-09-16 |
Mannkind Corporation |
Apparatus, system and method for measuring resistance of an inhaler
|
|
JP5659224B2
(ja)
|
2009-05-15 |
2015-01-28 |
ノバルティス アーゲー |
アルドステロンシンターゼ阻害剤としてのアリールピリジン
|
|
US8455522B2
(en)
|
2009-05-15 |
2013-06-04 |
Novartis Ag |
Benzoxazolone derivatives as aldosterone synthase inhibitors
|
|
MX2011012628A
(es)
|
2009-05-28 |
2011-12-14 |
Novartis Ag |
Derivados amino-propionicos sustituidos como inhibidores de neprilisina.
|
|
ES2582395T3
(es)
|
2009-05-28 |
2016-09-12 |
Novartis Ag |
Derivados aminobutíricos sustituidos como inhibidores de neprilisina
|
|
MY157166A
(en)
|
2009-06-12 |
2016-05-13 |
Mankind Corp |
Diketopiperazine microparticles with defined specific surface areas
|
|
EP3202394A1
(de)
|
2009-07-06 |
2017-08-09 |
Sanofi-Aventis Deutschland GmbH |
Wässrige insulinzubereitungen enthaltend methionin
|
|
WO2011020091A1
(en)
|
2009-08-14 |
2011-02-17 |
Phasebio Pharmaceuticals, Inc. |
Modified vasoactive intestinal peptides
|
|
WO2011056889A1
(en)
|
2009-11-03 |
2011-05-12 |
Mannkind Corporation |
An apparatus and method for simulating inhalation efforts
|
|
PE20121316A1
(es)
|
2009-11-13 |
2012-10-05 |
Sanofi Aventis Deutschland |
Composicion farmaceutica que comprende un agonista de glp-1 y metionina
|
|
PT2554183T
(pt)
|
2009-11-13 |
2018-07-09 |
Sanofi Aventis Deutschland |
Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
|
|
CN102712589B
(zh)
|
2009-11-17 |
2015-05-13 |
诺华股份有限公司 |
作为醛固酮合酶抑制剂的芳基-吡啶衍生物
|
|
JO2967B1
(en)
|
2009-11-20 |
2016-03-15 |
نوفارتس ايه جي |
Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
|
|
CN102666535B
(zh)
|
2009-11-30 |
2015-02-25 |
诺华股份有限公司 |
作为醛固酮合酶抑制剂的咪唑衍生物
|
|
WO2011123943A1
(en)
|
2010-04-09 |
2011-10-13 |
Mount Sinai Hospital |
Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
|
|
SG184988A1
(en)
|
2010-04-27 |
2012-11-29 |
Zealand Pharma As |
Peptide conjugates of glp-1 receptor agonists and gastrin and their use
|
|
WO2011143788A1
(en)
|
2010-05-17 |
2011-11-24 |
Zhejiang Beta Pharma Inc. |
Novel glucagon like peptide analogs, composition, and method of use
|
|
BR112012033060A2
(pt)
|
2010-06-21 |
2018-02-27 |
Mannkind Corp |
métodos de sistema de liberação de fármaco em pó seco
|
|
US20140148384A1
(en)
|
2010-08-30 |
2014-05-29 |
Sanofi-Aventis Deutschland Gmbh |
Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
|
|
US8877815B2
(en)
|
2010-11-16 |
2014-11-04 |
Novartis Ag |
Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
|
|
US8673974B2
(en)
|
2010-11-16 |
2014-03-18 |
Novartis Ag |
Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
|
|
MX345501B
(es)
|
2010-12-16 |
2017-02-02 |
Novo Nordisk As |
Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
|
|
US20140004198A1
(en)
*
|
2011-01-19 |
2014-01-02 |
Novo Nordisk A/S |
Glp-1 particles and compositions
|
|
AU2012236150B2
(en)
|
2011-04-01 |
2016-03-31 |
Mannkind Corporation |
Blister package for pharmaceutical cartridges
|
|
KR101972836B1
(ko)
|
2011-04-12 |
2019-04-29 |
노보 노르디스크 에이/에스 |
이중 아실화된 ｇｌｐ-1 유도체
|
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
|
EP2717902B1
(en)
|
2011-06-06 |
2018-01-24 |
Phasebio Pharmaceuticals, Inc. |
Use of modified vasoactive intestinal peptides in the treatment of hypertension
|
|
WO2012174472A1
(en)
|
2011-06-17 |
2012-12-20 |
Mannkind Corporation |
High capacity diketopiperazine microparticles
|
|
CN108079281A
(zh)
|
2011-08-29 |
2018-05-29 |
赛诺菲-安万特德国有限公司 |
用于2型糖尿病患者中的血糖控制的药物组合
|
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
|
BR112014009686A2
(pt)
|
2011-10-24 |
2018-08-07 |
Mannkind Corp |
composição analgésica inalável, pó seco e método para tratar dor
|
|
CA2853884A1
(en)
|
2011-11-03 |
2013-05-10 |
Zealand Pharma A/S |
Glp-1 receptor agonist peptide gastrin conjugates
|
|
AU2012360998B2
(en)
|
2011-12-29 |
2017-11-23 |
Novo Nordisk A/S |
Dipeptide comprising a non-proteogenic amino acid
|
|
HRP20190489T1
(hr)
|
2012-03-22 |
2019-05-03 |
Novo Nordisk A/S |
Pripravci koji sadrže sredstvo za unošenje i njihova priprava
|
|
EP2827885B1
(en)
|
2012-03-22 |
2018-08-15 |
Novo Nordisk A/S |
Compositions of glp-1 peptides and preparation thereof
|
|
US9993430B2
(en)
|
2012-06-20 |
2018-06-12 |
Novo Nordisk A/S |
Tablet formulation comprising semaglutide and a delivery agent
|
|
WO2014010586A1
(ja)
|
2012-07-10 |
2014-01-16 |
武田薬品工業株式会社 |
注射用製剤
|
|
AU2013289957B2
(en)
|
2012-07-12 |
2017-02-23 |
Mannkind Corporation |
Dry powder drug delivery systems and methods
|
|
MY170671A
(en)
|
2012-07-23 |
2019-08-26 |
Zealand Pharma As |
Glucagon analogues
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
WO2014066856A1
(en)
|
2012-10-26 |
2014-05-01 |
Mannkind Corporation |
Inhalable influenza vaccine compositions and methods
|
|
UY35144A
(es)
|
2012-11-20 |
2014-06-30 |
Novartis Ag |
Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
|
|
TWI641381B
(zh)
|
2013-02-04 |
2018-11-21 |
法商賽諾菲公司 |
胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
|
|
JP6295277B2
(ja)
|
2013-02-14 |
2018-03-14 |
ノバルティス アーゲー |
Ｎｅｐ（中性エンドペプチダーゼ）阻害剤としての置換ビスフェニルブタン酸ホスホン酸誘導体
|
|
KR102246914B1
(ko)
|
2013-03-15 |
2021-04-30 |
맨카인드 코포레이션 |
미세결정성 디케토피페라진 조성물 및 방법
|
|
SMT201800492T1
(it)
|
2013-05-02 |
2018-11-09 |
Novo Nordisk As |
Dosaggio orale di composti di glp-1
|
|
CN114848614A
(zh)
|
2013-07-18 |
2022-08-05 |
曼金德公司 |
热稳定性干粉药物组合物和方法
|
|
TW201536814A
(zh)
|
2013-07-25 |
2015-10-01 |
Novartis Ag |
用於治療心臟衰竭之合成環狀多肽
|
|
PE20160991A1
(es)
|
2013-07-25 |
2016-10-15 |
Novartis Ag |
Bioconjugados de polipeptidos de apelina sintetica
|
|
EP3030294B1
(en)
|
2013-08-05 |
2020-10-07 |
MannKind Corporation |
Insufflation apparatus
|
|
SI3057984T1
(sl)
|
2013-10-17 |
2018-10-30 |
Zealand Pharma A/S |
Acilirani glukagonski analogi
|
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
US10093713B2
(en)
|
2013-11-06 |
2018-10-09 |
Zealand Pharma A/S |
GIP-GLP-1 dual agonist compounds and methods
|
|
EA035688B1
(ru)
|
2013-11-06 |
2020-07-27 |
Зилэнд Фарма А/С |
Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
|
|
RU2016132340A
(ru)
|
2014-01-09 |
2018-02-14 |
Санофи |
Стабилизированные фармацевтические составы на основе инсулина аспарта
|
|
KR20160104724A
(ko)
|
2014-01-09 |
2016-09-05 |
사노피 |
인슐린 유사체 및/또는 인슐린 유도체의 안정화된 약제학적 제형
|
|
CN105899191B
(zh)
|
2014-01-09 |
2020-06-16 |
赛诺菲 |
胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂
|
|
US10307464B2
(en)
|
2014-03-28 |
2019-06-04 |
Mannkind Corporation |
Use of ultrarapid acting insulin
|
|
US11052132B2
(en)
|
2014-05-08 |
2021-07-06 |
Phasebio Pharmaceuticals, Inc. |
Methods and compositions for treating cystic fibrosis
|
|
US10561806B2
(en)
|
2014-10-02 |
2020-02-18 |
Mannkind Corporation |
Mouthpiece cover for an inhaler
|
|
TWI705973B
(zh)
|
2014-10-29 |
2020-10-01 |
丹麥商西蘭製藥公司 |
Ｇｉｐ促效劑化合物及方法
|
|
TWI758239B
(zh)
|
2014-12-12 |
2022-03-21 |
德商賽諾菲阿凡提斯德意志有限公司 |
甘精胰島素/利司那肽固定比率配製劑
|
|
CN105820233B
(zh)
*
|
2015-01-04 |
2021-06-15 |
甘李药业股份有限公司 |
一种胰岛素衍生物的制备方法
|
|
WO2016116842A1
(en)
|
2015-01-23 |
2016-07-28 |
Novartis Ag |
Synthetic apelin fatty acid conjugates with improved half-life
|
|
CA2976038A1
(en)
|
2015-02-09 |
2016-08-18 |
Phasebio Pharmaceuticals, Inc. |
Methods and compositions for treating muscle disease and disorders
|
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患治療
|
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患之治療
|
|
TWI707867B
(zh)
|
2015-04-16 |
2020-10-21 |
丹麥商西蘭製藥公司 |
醯化之昇糖素類似物
|
|
JOP20190086A1
(ar)
|
2016-10-21 |
2019-04-18 |
Novartis Ag |
مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
|
|
WO2018104561A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
|
TWI847306B
(zh)
|
2017-08-24 |
2024-07-01 |
丹麥商諾佛 儂迪克股份有限公司 |
Ｇｌｐ-１組成物及其用途
|
|
EP4299118A3
(en)
|
2018-02-02 |
2024-04-10 |
Novo Nordisk A/S |
Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
|
|
UY38072A
(es)
|
2018-02-07 |
2019-10-01 |
Novartis Ag |
Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
|
|
UY38485A
(es)
|
2018-11-27 |
2020-06-30 |
Novartis Ag |
Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
|
|
JP7657151B2
(ja)
|
2018-11-27 |
2025-04-04 |
ノバルティス アーゲー |
代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン／ケキシン９型（ｐｃｓｋ９）阻害剤としての環状ペプチド
|
|
US20230089867A1
(en)
|
2018-11-27 |
2023-03-23 |
Novartis Ag |
Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
|
|
GB201917723D0
(en)
*
|
2019-12-04 |
2020-01-15 |
Nv Rose Llc |
Stable liquid formulations of glucagon-like peptide 1 or analogues thereof
|
|
BR112022013795A2
(pt)
|
2020-02-18 |
2022-09-13 |
Novo Nordisk As |
Composição farmacêutica líquida, e, kit
|
|
TW202333563A
(zh)
|
2021-11-12 |
2023-09-01 |
瑞士商諾華公司 |
用於治療疾病或障礙之二胺基環戊基吡啶衍生物
|
|
AR127698A1
(es)
|
2021-11-23 |
2024-02-21 |
Novartis Ag |
Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
|
|
WO2024123812A1
(en)
|
2022-12-05 |
2024-06-13 |
Shattuck Labs, Inc. |
Fusion proteins for the treatment of cardiometabolic diseases
|
|
KR20260015867A
(ko)
|
2023-05-24 |
2026-02-03 |
노파르티스 아게 |
질환 또는 장애 치료용 나프티리디논 유도체
|